Results 51 to 60 of about 1,634 (161)

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea

Human Vaccines & Immunotherapeutics
The current standard-of-care prophylaxis for respiratory syncytial virus (RSV) is primarily administered to high-risk infant populations. We conducted a cost-effectiveness analysis to determine the economically justifiable price of nirsevimab compared ...
Hyun Jin Han, Semin Jang, Ryu Dahye, Haeseon Lee, Jiyeon Lee, Eun Jin Bae, Samira Soudani, Hae Sun Suh   +7 more
doaj   +1 more source

Sociodemographic Characteristics of Infants Receiving Nirsevimab

JAMA Network Open
This cohort study investigates inequalities by sociodemographic group in the receipt of nirsevimab immunization by infants in France from 2023 to 2024.
Boutin, Salomé, Bertrand, Marion, Cohen, Jérémie F., Zureik, Mahmoud, Chalumeau, Martin, Jabagi, Marie-Joëlle   +5 more
openaire   +2 more sources

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023–2024 Season in Andalusia, Spain (NIRSEGRAND)

Vaccines
Background: Nirsevimab was indicated in a population level for all infants < 6 months during the 2023–2024 season in Andalusia (southern Spain). Our aim was to analyse the effect of nirsevimab in the reduction in complications in infants hospitalised for
David Moreno-Pérez, Aleksandra Korobova, Francisco de Borja Croche-Santander, Ana Cordón-Martínez, Olga Díaz-Morales, Leticia Martínez-Campos, Elena Pérez-González, María del Carmen Martínez-Padilla, Juan Luis Santos-Pérez, Jaime Brioso-Galiana, María Isabel Sánchez-Códez, Jorge Del Diego-Salas, Mario Rivera-Izquierdo, Nicola Lorusso   +13 more
doaj   +1 more source

Incidence of Respiratory Syncytial Virus Infection Among Patients Aged Less Than 2 Years: A Retrospective Study From an Italian Southern Region in Years 2018–2023

Influenza and Other Respiratory Viruses, Volume 20, Issue 5, May 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is one of the most common viruses infecting nearly all children worldwide within the first 2 years of life, requiring hospitalization for over 80% of cases in infants under the age of 1. The aim of this study was to evaluate the epidemiological impact of RSV infections on hospital admissions among
Giuseppe Di Martino, Pamela Di Giovanni, Federica Vaccaro, Francesca Romana Cascavilla, Carla Di Marzio, Livia Tognaccini, Edoardo Trebbi, Teresa Aita, Ferdinando Romano, Tommaso Staniscia   +9 more
wiley   +1 more source

Reluctance of parents to immunize their children with nirsevimab

Anales de Pediatría (English Edition)
2025
Piñeiro Pérez, Roi, Galán Arévalo, Sonsoles, Risso, Milagros, Hidalgo Montes, Inmaculada, López Escobar, Alejandro   +4 more
openaire   +3 more sources

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

Acceptance of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Neonates: A Cross-Sectional Survey in Emilia-Romagna, Italy

Vaccines
Background: Respiratory syncytial virus (RSV) bronchiolitis remains a leading cause of hospitalization in infants, particularly those with risk factors such as prematurity or chronic diseases.
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie Aricò, Angela Lanzoni, Beatrice Rita Campana, Marta Niceforo, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +1 more source

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods A cohort model was ...
Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W. Law, Diana Mendes   +9 more
doaj   +1 more source

Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis

Pediatric Reports
Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy ...
Brody J. Lipsett, Benjamin N. Fogel, Katherine E. Shedlock, Ian M. Paul, Eric W. Schaefer, Ruth E. Gardner, Leah D. Kaye, Steven D. Hicks   +7 more
doaj   +1 more source